Influence of prior and subsequent pregnancy on breast cancer prognosis.

PURPOSE AND METHODS The prognostic influence of pregnancies 5 years before (n = 173) and after (n = 50) breast cancer diagnosis was investigated in 2,119 women less than 50 years of age with a primary operable breast cancer. The main end point was distant metastasis. Univariate and multivariate analyses were performed using the Cox proportional hazards model. In the analyses of the effect of pregnancy after diagnosis of breast cancer, a Cox model with a time-dependent covariate was applied. RESULTS Women with a pregnancy before diagnosis had slightly larger tumors than the control group. However, they did not differ with respect to nodal status and estrogen receptor (ER) status. There was no evidence that women with a pregnancy during the 5-year period preceding breast cancer diagnosis had a worse prognosis compared with women without pregnancy during the same period. Similarly, there was no evidence that women with a pregnancy after breast cancer diagnosis had a worse prognosis. CONCLUSION The hormonal changes associated with pregnancy thus seem to have little, if any, influence on the prognosis of breast cancer. In the present study, at least, there was no indication of a worse prognosis. In fact, the relative hazard for women who became pregnant after diagnosis of breast cancer in comparison with women without a subsequent pregnancy was 0.48 (P = .14), which suggested a possible decreased risk of distant dissemination.

Download Full-text

Prognostic Factors and Survival Outcomes among Patients with Breast Cancer and Brain Metastases at Diagnosis: A National Cancer Database Analysis

Oncology ◽

10.1159/000512212 ◽

2021 ◽

Vol 99 (5) ◽

pp. 280-291

Author(s):

Brittney S. Zimmerman ◽

Danielle Seidman ◽

Krystal P. Cascetta ◽

Meng Ru ◽

Erin Moshier ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Proportional Hazards ◽

Proportional Hazards Model ◽

Breast Cancer Diagnosis ◽

Cox Proportional Hazards ◽

Cox Proportional Hazards Model ◽

National Cancer Database ◽

Hazards Model ◽

Sites Of Metastases

Introduction: The aim of this study was to assess for clinicopathologic and socioeconomic features that predict improved survival for patients with advanced breast cancer with synchronous brain metastases at diagnosis. Methods: We utilized the National Cancer Database (NCDB) to identify all patients with brain metastases present at diagnosis, with adequate information on receptor status (ER, PR, Her2), clinical T stage of cT1-4, clinical M1, with 3,943 patients available for analysis. The association between brain metastases patterns and patient/disease variables was examined by robust Poisson regression model. Cox proportional hazards model was used to quantify the associations between overall survival (OS) and these variables. Results: In univariable analysis, OS was significantly associated with the number of sites of metastases (p < 0.0001). Patients with 2 or more additional extracranial sites of metastases had significantly worse OS (median 8.8 months, 95% confidence interval [CI] 7.8, 9.9) than patients with brain metastases only (median OS 10.6 months, 95% CI 9.4, 12.9) or brain metastases plus one other extracranial site of metastases (median OS 13.1 months, 95% CI 11.8, 14.4). Risk factors which predicted poor prognosis included triple-negative disease, high comorbidity score, poorly differentiated tumors, invasive lobular histology, multi-organ involvement of metastases, and government or lack of insurance. Factors which improve survival include younger age and Hispanic race. Discussion/Conclusion: Using a large NCDB, we identified various factors associated with prognosis for patients with brain metastases at the time of breast cancer diagnosis. Insurance status and related socioeconomic challenges provide potential areas for improvement in care for these patients. This information may help stratify patients into prognostic categories at the time of diagnosis to improve treatment plans.

Download Full-text

Adherence to the Mediterranean Diet and Mortality after Breast Cancer

Nutrients ◽

10.3390/nu12123649 ◽

2020 ◽

Vol 12 (12) ◽

pp. 3649

Author(s):

Matteo Di Maso ◽

Luigino Dal Maso ◽

Livia S. A. Augustin ◽

Antonella Puppo ◽

Fabio Falcini ◽

...

Keyword(s):

Breast Cancer ◽

Mediterranean Diet ◽

Cancer Diagnosis ◽

Cancer Mortality ◽

Unsaturated Fatty Acids ◽

Dietary Habits ◽

Cox Model ◽

Breast Cancer Mortality ◽

Breast Cancer Diagnosis ◽

The Mediterranean

Adherence to Mediterranean diet has been consistently associated with a reduced mortality in the general population, but evidence for women with breast cancer is scanty. Methods: A cohort of 1453 women with breast cancer diagnosed between 1991 and 1994 in northern Italy was followed-up for vital status for 15 years after diagnosis. The pre-diagnostic habitual diet was assessed through a structured questionnaire and adherence to the Mediterranean diet was evaluated through the Mediterranean Diet Score. Hazard ratios (HR) of death with confidence intervals (CI) were estimated using Cox model, adjusting for potential confounders. Results: Compared to women who scarcely adhere to the Mediterranean diet (n = 332, 22.8%), those highly adherent (n = 500, 34.4%) reported higher intakes of carbohydrates, mono-unsaturated and poly-unsaturated fatty acids, vitamins, folate, and carotenoids, and lower intakes of cholesterol and animal proteins. Adherence to the Mediterranean diet was associated with a better prognosis: 15-year overall survival of 63.1% for high and 53.6% for low adherence, respectively (p = 0.013). HR for all-cause mortality was 0.72 (95% CI: 0.57−0.92) and HR for breast cancer mortality was 0.65 (95% CI: 0.43−0.98) for women 55 years and older. No significant association emerged for breast cancer mortality in the total cohort. Conclusions: Although dietary habits may have changed after breast cancer diagnosis, these findings indicate that women who ate according to the Mediterranean dietary pattern prior to their diagnosis may have greater chance of a favorable prognosis after breast cancer diagnosis compared to those who did not.

Download Full-text

Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study

International Journal of Cancer ◽

10.1002/ijc.31411 ◽

2018 ◽

Vol 143 (5) ◽

pp. 1093-1104 ◽

Cited By ~ 10

Author(s):

Louise Eriksson ◽

Jonas Bergh ◽

Keith Humphreys ◽

Fredrik Wärnberg ◽

Sven Törnberg ◽

...

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Cancer Diagnosis ◽

Breast Cancer Diagnosis ◽

Population Based ◽

Breast Cancer Prognosis ◽

Cancer Prognosis

Download Full-text

Use of a Wearable EEG Headband as a Meditation Device for Women With Newly Diagnosed Breast Cancer: A Randomized Controlled Trial

Integrative Cancer Therapies ◽

10.1177/1534735419878770 ◽

2019 ◽

Vol 18 ◽

pp. 153473541987877 ◽

Cited By ~ 1

Author(s):

Denise M. Millstine ◽

Anjali Bhagra ◽

Sarah M. Jenkins ◽

Ivana T. Croghan ◽

Daniela L. Stan ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Surgical Treatment ◽

Cancer Diagnosis ◽

Controlled Trial ◽

Intervention Group ◽

Breast Cancer Diagnosis ◽

Control Group ◽

Breast Cancer Patients

Background: Breast cancer diagnosis and treatment affect quality of life and stress and are associated with fatigue. Meditation interventions are effective strategies for patients with breast cancer but are often limited by poor access, high cost, substantial time commitment, and poor adherence. In this feasibility study, we investigated the use of a portable, wearable, electroencephalographic device for guided meditation practices by breast cancer patients during the period from breast cancer diagnosis until 3 months after surgical treatment. Methods: We enrolled women (age = 20-75 years) who had received a recent diagnosis of breast cancer and planned to undergo surgical treatment. Participants were randomly assigned to perform guided meditation with the device (intervention group) or receive CD-based stress-reduction education (control group). Surveys were used to measure stress, quality of life, and fatigue at baseline, within 4 days before surgery, up to 14 days after surgery, and at 3 months after surgery. Results: In the intervention group, 15 of 17 participants (88.2%) completed the study; in the control group, 13 of 13 participants completed the study (100%). Participants in both groups had less fatigue and stress and improved quality of life at 2 weeks and 3 months after surgery compared with baseline, but there were no significant intergroup differences at any time point. Conclusion: The use of this wearable electroencephalographic device for meditation is a feasible strategy for patients with breast cancer.

Download Full-text

Data Mining and Machine Learning Approaches in Breast Cancer Biomedical Research

Advances in Business Information Systems and Analytics - Sentiment Analysis and Knowledge Discovery in Contemporary Business ◽

10.4018/978-1-5225-4999-4.ch011 ◽

2019 ◽

pp. 175-204

Author(s):

Gunavathi Chellamuthu ◽

Kannimuthu S. ◽

Premalatha K.

Keyword(s):

Breast Cancer ◽

Machine Learning ◽

Data Mining ◽

Cancer Diagnosis ◽

Biomedical Research ◽

Breast Cancer Diagnosis ◽

Machine Learning Algorithms ◽

Cancer Prognosis ◽

Whole Process ◽

Breast Lumps

Breast cancer is the most common invasive cancer in females worldwide. Breast cancer diagnosis and breast cancer prognosis are the two important challenges for the researchers in the medical field and also for the practitioners. If the cells in the breast start to grow without any control, it leads to cancer. Normally, the growth of the lump can be seen using x-ray. The benign and malignant breast lumps are distinguished during breast cancer diagnosis. The prognosis process predicts the period at which the breast cancer is likely to reappear in patients who have had their cancers removed. Data mining techniques and machine learning algorithms are mostly used in the whole process of breast cancer diagnosis and treatment. They utilize the large volume of breast cancer data for extracting knowledge. The application of data mining and machine learning methods in biomedical research is presently vital and crucial in efforts to transform intelligently all available data into valuable knowledge.

Download Full-text

Demographic and clinicopathologic characteristics in patients with invasive breast cancer receiving metformin.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e11593 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e11593-e11593

Author(s):

Sercan Aksoy ◽

Mehmet Ali Nahit Sendur ◽

Kadri Altundag

Keyword(s):

Breast Cancer ◽

Cancer Diagnosis ◽

Lower Incidence ◽

Breast Cancer Mortality ◽

Disease Free Survival ◽

Breast Cancer Diagnosis ◽

Control Group ◽

Diabetic Patients ◽

Free Survival ◽

Disease Free

e11593 Background: There was contradictory data with metformin use on breast cancer risk, but there is growing evidence that the use of metformin in diabetic patients was associated with lower risks of breast cancer mortality and incidence. The effect of metformin on clinical and pathological properties of breast cancer was not known exactly, we aimed to investigate the demographic and clinico-pathological characteristics of patients with metformin users at the time of breast cancer diagnosis. Methods: Patients with breast cancer diagnosed from 2000 to 2012 in our clinic were retrospectively analyzed. Patient’s demographics, including survival data and tumor characteristics were obtained from medical charts. Breast cancer patients who were taking metformin at the time of breast cancer diagnosis were enrolled as metformin users (n=148), where the patients matched with the same age who were not taking metformin were included as a control group (n=636). Results: A total of 784 patients were included in this study. Median age of both metformin users and nonusers was 57 (23-87). There were no significant differences in baseline tumor size (P=0.60), tumor stage (P=0.76) node positivity (P=0.13) between the two groups. Metformin user patients compared to nonusers had significantly lower incidence of histological grade III tumor (P=0.03). A similar significant trend for lower incidence of triple-negative (P=0.01) and higher incidence ER positivity (P=0.008), PR positivity (P=0.01) was also seen in metformin users. In survival analysis the estimated median disease free survival (DFS) was 118 months in metformin users whereas 69 months in nonusers (P=0.09). Median overall survival (OS) could not be obtained due to low events. In patients with metformin users OS rate was 98.4%, 97.1%, and 93.8% and in nonusers was 99.6%, 94.4% and 90.5% the first, third, and fifth years, respectively. Conclusions: The use of metformin at the time of breast cancer diagnosis was associated with better clinico-pathological properties and non-significantly improved disease free survival in patients with breast cancer.

Download Full-text